ATLAS Molecular Pharma succeeded with the competitive NEOTEC call (CDTI), obtaining a grant for a total amount of 213.000 EUR during the period 2017-2018. The NEOTEC Program aims to support the creation and consolidation of technology-based companies and it takes into account the creation of new technology and the innovation character of the business initiative.
José María Mato, Óscar Millet and Joaquín Castilla present their research on Porphyria and Prion diseases, and how ATLAS molecular pharma is a clear example of translational biomedical research. Related info: Eitb.eus Radio https://vimeo.com/206707728
The Chassys platform has been successfully applied for the identification of a series of putative pharmacological chaperones for the treatment of congenital erythropoietic porphyria. One of them is currently being validated, with most promising results. See also “Una molécula ‘carabina’ para aplacar la porfiria congénita”.
Join us at BioSpain 2016 in Bilbao, September 28th – 30th. If you want to find out more about what we do and are a potential Investor or Partner, please contact us through the BioSpain Partnering platform or by email to noccleston@atlasmolecularpharma.com
The new company, Atlas Molecular Pharma, will further develop its proprietary technology to act as a “drug discovery engine” for the discovery and development of drugs called pharmacological chaperones, which act by restoring defective protein activity – this is a common pathological mechanism which Atlas will target, and is present in around 80% of the [...]
